Trade Summary

5 days ago, Benatti Luca, serving as Dir at Quince Therapeutics, Inc. (QNCX), sold 50,000 shares at $3.47 per share, for a total transaction value of $173,500.00. Following this transaction, Benatti Luca now holds 39,179 shares of QNCX.

This sale represents a 56.00% decrease in Benatti Luca's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, December 26, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 29, 2025, 3 days after the trade was made.

Quince Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.